and DNA Repository (RUCDR), and full anonymization of data and biomaterials. The questionnaire (available at nimhgenetics.org) was primarily comprised of the Composite International Diagnostic Interview – Short Form (CIDI-SF) (Kessler et al. 1998b; Kessler et al. 1998a; Wittchen 1994), modified to screen for lifetime diagnoses (AD, drug dependence, major depressive episode/s, generalized anxiety disorder, specific phobia, social phobia, agoraphobia, panic attacks, and obsessive compulsive disorder). The questionnaire also included other components assessing various traits and disorders: Fagerström Test for Nicotine Dependence (FTND) (Heatherton et al. 1991); Eysenck brief neuroticism and extraversion scales (Eysenck, Eysenck, and Barrett 1985); sexual identity; height and body mass index (BMI); psychosis and mania screens; ancestry (race/ethnicity) (Nurnberger, Jr. et al. 1994) for each grandparent; and basic demographics. We scored the dichotomous presence/absence of individual disorders according to the CIDI-SF (Kessler et al. 1998a) scoring memo (Nelson, Kessler, and Mroczek 2001). For the Molecular Genetics of Schizophrenia (MGS2) genome wide association study (GWAS) of schizophrenia (Shi et al. 2009), we genotyped 3,827 (2,817 EA and 1,010 AA) control samples with the Affymetrix 6.0 array, selected for eligibility based on previous laboratory study of genotypic ancestral background and DNA quality. Of these, over 95% (3,667) of the
